These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 28503750

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
    Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL.
    Liver Int; 2019 May; 39(5):941-949. PubMed ID: 30721572
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H, Zeng Z, Zhang H, Zhou X, Guan L, Deng W, Xu L.
    Biol Pharm Bull; 2015 May; 38(5):694-702. PubMed ID: 25947915
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W.
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, Chim AM, Chan CK, Leung JK, Chu WC, Woo J, Chan HL.
    J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
    [Abstract] [Full Text] [Related]

  • 8. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
    Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL.
    J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD.
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [Abstract] [Full Text] [Related]

  • 11. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH, Rolin B, Rakipovski G, Skovsted GF, Madsen A, Kolstrup S, Schou-Pedersen AM, Skat-Rørdam J, Lykkesfeldt J, Tveden-Nyborg P.
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA, NN8022-1922 Study Group.
    JAMA; 2015 Aug 18; 314(7):687-99. PubMed ID: 26284720
    [Abstract] [Full Text] [Related]

  • 13. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study.
    Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A.
    Int J Food Sci Nutr; 2016 Jun 18; 67(4):461-9. PubMed ID: 26983396
    [Abstract] [Full Text] [Related]

  • 14. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X, Wu X, Jia Y, Fu J, Zhang L, Jiang T, Liu J, Wang G.
    J Diabetes Res; 2021 Jun 18; 2021():3715026. PubMed ID: 34660809
    [Abstract] [Full Text] [Related]

  • 15. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
    He Q, Sha S, Sun L, Zhang J, Dong M.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):196-203. PubMed ID: 27208776
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review.
    Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, Younossi ZM.
    World J Gastroenterol; 2016 Jul 21; 22(27):6318-27. PubMed ID: 27468220
    [Abstract] [Full Text] [Related]

  • 17. Exercise-Induced Weight Loss is More Effective than Dieting for Improving Adipokine Profile, Insulin Resistance, and Inflammation in Obese Men.
    Khoo J, Dhamodaran S, Chen DD, Yap SY, Chen RY, Tian RH.
    Int J Sport Nutr Exerc Metab; 2015 Dec 21; 25(6):566-75. PubMed ID: 26011919
    [Abstract] [Full Text] [Related]

  • 18. Effects of a combined intervention with a lentil protein hydrolysate and a mixed training protocol on the lipid metabolism and hepatic markers of NAFLD in Zucker rats.
    Martínez R, Kapravelou G, Donaire A, Lopez-Chaves C, Arrebola F, Galisteo M, Cantarero S, Aranda P, Porres JM, López-Jurado M.
    Food Funct; 2018 Feb 21; 9(2):830-850. PubMed ID: 29364302
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
    Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW.
    J Hepatol; 2016 Feb 21; 64(2):399-408. PubMed ID: 26394161
    [Abstract] [Full Text] [Related]

  • 20. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A.
    Diabetologia; 2020 Nov 21; 63(11):2434-2445. PubMed ID: 32865597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.